Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Cash & Current Investments (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Cash & Current Investments for 14 consecutive years, with $50.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 53.14% year-over-year to $50.9 million, compared with a TTM value of $50.9 million through Dec 2025, down 53.14%, and an annual FY2025 reading of $50.9 million, down 53.14% over the prior year.
  • Cash & Current Investments was $50.9 million for Q4 2025 at Karyopharm Therapeutics, up from $45.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $260.4 million in Q1 2023 and bottomed at $45.9 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $139.4 million, with a median of $146.1 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments crashed 76.35% in 2022, then surged 390.65% in 2023.
  • Year by year, Cash & Current Investments stood at $228.6 million in 2021, then plummeted by 37.08% to $143.8 million in 2022, then soared by 33.09% to $191.4 million in 2023, then crashed by 43.21% to $108.7 million in 2024, then tumbled by 53.14% to $50.9 million in 2025.
  • Business Quant data shows Cash & Current Investments for KPTI at $50.9 million in Q4 2025, $45.9 million in Q3 2025, and $47.9 million in Q2 2025.